Analisi facoltativa del prodotto
Con il tuo consenso utilizziamo analisi limitate e rispettose della privacy per capire quali percorsi di ricerca funzionano. Non usiamo tracker pubblicitari né registrazioni delle sessioni. Puoi modificare questa scelta nelle Preferenze. Leggi la Informativa sulla privacy.
Illumina, Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $39.1B | |
|---|---|---|
| Revenue (ttm) | 4.5B | |
| Net income (ttm) | 824M | |
| EPS (ttm) | $5.37 | |
| Shares out | 151M | |
| P/E (trailing) | 53.8x | |
| P/E (forward) | 40.3x | |
| Volume | 2,029,934 | |
| Beta | 1.42 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-01-02 | 2023-01-01 | 2023-12-31 | 2024-12-29 | 2025-12-28 | Trend |
| Revenue | $4.53B | $4.58B | $4.50B | $4.37B | $4.34B | -1.0% |
| Gross profit | $3.15B | $2.97B | $2.74B | $2.86B | $2.87B | -2.3% |
| Operating income | $-123.0M | $-4.18B | $-1.07B | $-833.0M | $807.0M | — |
| Net income | $762.0M | $-4.40B | $-1.16B | $-1.22B | $850.0M | +2.8% |
| EPS (diluted) | $4.90 | $-28.00 | $-7.34 | $-7.69 | $5.45 | +2.7% |
| EBITDA | $128.0M | $-3.79B | $-1.07B | $-725.0M | $1.46B | +83.7% |
| R&D | $1.19B | $1.32B | $1.35B | $1.17B | $967.0M | -5.0% |
| SG&A | $2.09B | $1.30B | $1.61B | $1.09B | $1.09B | -15.1% |
Recent company headlines from major financial publishers.
The modal base path reflects management's FY2026 guidance for reported revenue and operating margin. Clinical consumables expansion at mid-teens offsets mid-to-high single-digit research declines. This trajectory generates Fair value of $119.53, implying -53.9% return relative to $259.19.
In the Bull case, clinical sequencing expands rapidly across oncology and rare disease diagnostics, driving mid-teens clinical consumables growth and enabling FY2027 revenue to reach high single digits. Operating margins expand via high consumable pull-through, supporting Potential value of $146.73. Notably, even this optimistic outcome remains well below $259.19.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 9.3% | $122 | $124 | $127 | $129 | $132 |
| 9.8% | $119 | $121 | $123 | $125 | $127 |
| 10.3% | $116 | $118 | $120 | $121 | $124 |
| 10.8% | $114 | $115 | $117 | $118 | $120 |
| 11.3% | $111 | $113 | $114 | $115 | $117 |
Upcoming earnings date and setup when available.
Il rating riportato dall'edizione di ricerca pubblicata ogni mese. Un rating confronta il prezzo alla data dell'analisi con il valore equo; non indica se la valutazione si è rivelata corretta.
| Anno | gen | feb | mar | apr | mag | giu | lug | ago | set | ott | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
